Deucravacitinib
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
No
Active ingredient: Deucravacitinib
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
17/02/2025 Deucravacitinib for moderate-to-severe chronic plaque psoriasis (opens in new tab)
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended deucravacitinib for inclusion on the MOH List of Subsidised Drugs for treating moderate-to-severe chronic plaque psoriasis. The decision was based on the unfavourable clinical and cost effectiveness of deucravacitinib compared with adalimumab, and the unacceptable price-volume agreement proposed by the company.
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch (opens in new tab). The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch (opens in new tab) for the most updated product information. |
Oral
* Clinical information is available for this product.